Perioperative and Mid-Term Oncological and Functional Outcomes After Partial Nephrectomy for Entirely Endophytic Renal Tumors: A Prospective Multicenter Observational Study (The RECORD2 Project)
Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patient Selection and Dataset
2.2. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ljungberg, B.; Albiges, L.; Abu-Ghanem, Y.; Bedke, J.; Capitanio, U.; Dabestani, S.; Fernández-Pello, S.; Giles, R.H.; Hofmann, F.; Hora, M.; et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. Eur. Urol. 2022, 82, 399–410. [Google Scholar] [CrossRef]
- Bradshaw, A.W.; Autorino, R.; Simone, G.; Yang, B.; Uzzo, R.G.; Porpiglia, F.; Capitanio, U.; Porter, J.; Bertolo, R.; Minervini, A.; et al. Robotic partial nephrectomy vs. minimally invasive radical nephrectomy for clinical T2a renal mass: A propensity score-matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. BJU Int. 2020, 126, 114–123. [Google Scholar] [CrossRef] [PubMed]
- Mari, A.; Di Maida, F.; Tellini, R.; Campi, R.; Sforza, S.; Cocci, A.; Siena, G.; Vittori, G.; Tuccio, A.; Masieri, L.; et al. Oncologic outcomes in patients treated with endoscopic robot assisted simple enucleation (ERASE) for renal cell carcinoma: Results from a tertiary referral center. Eur. J. Surg. Oncol. 2019, 45, 1977–1982. [Google Scholar] [CrossRef]
- Capitanio, U.; Terrone, C.; Antonelli, A.; Minervini, A.; Volpe, A.; Furlan, M.; Matloob, R.; Regis, F.; Fiori, C.; Porpiglia, F.; et al. Nephron-sparing techniques independently decrease the risk of cardiovascular events relative to radical nephrectomy in patients with a T1a-T1b renal mass and normal preoperative renal function. Eur. Urol. 2015, 67, 683–689. [Google Scholar] [CrossRef] [PubMed]
- Antonelli, A.; Minervini, A.; Sandri, M.; Bertini, R.; Bertolo, R.; Carini, M.; Furlan, M.; Larcher, A.; Mantica, G.; Mari, A.; et al. Below Safety Limits, Every Unit of Glomerular Filtration Rate Counts: Assessing the Relationship Between Renal Function and Cancer-specific Mortality in Renal Cell Carcinoma. Eur. Urol. 2018, 74, 661–667. [Google Scholar] [CrossRef] [PubMed]
- Campi, R.; Di Maida, F.; Lane, B.R.; De Cobelli, O.; Sanguedolce, F.; Hatzichristodoulou, G.; Antonelli, A.; Noyes, S.; Mari, A.; Grosso, A.A.; et al. Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2022, 48, 687–693. [Google Scholar] [CrossRef]
- Tuderti, G.; Brassetti, A.; Mastroianni, R.; Misuraca, L.; Bove, A.; Anceschi, U.; Ferriero, M.; Guaglianone, S.; Gallucci, M.; Simone, G. Expanding the limits of nephron-sparing surgery: Surgical technique and mid-term outcomes of purely off-clamp robotic partial nephrectomy for totally endophytic renal tumors. Int. J. Urol. Off. J. Jpn. Urol. Assoc. 2022, 29, 282–288. [Google Scholar] [CrossRef]
- Mari, A.; Tellini, R.; Porpiglia, F.; Antonelli, A.; Schiavina, R.; Amparore, D.; Bertini, R.; Brunocilla, E.; Capitanio, U.; Checcucci, E.; et al. Perioperative and Mid-term Oncological and Functional Outcomes After Partial Nephrectomy for Complex (PADUA Score ≥10) Renal Tumors: A Prospective Multicenter Observational Study (the RECORD2 Project). Eur. Urol. Focus 2021, 7, 1371–1379. [Google Scholar] [CrossRef]
- Ito, H.; Uemura, K.; Ikeda, M.; Jikuya, R.; Kondo, T.; Tatenuma, T.; Kawahara, T.; Komeya, M.; Ito, Y.; Muraoka, K.; et al. Impacts of Complete Endophytic Renal Tumors on Surgical, Functional, and Oncological Outcomes of Robot-Assisted Partial Nephrectomy. J. Endourol. 2024, 38, 347–352. [Google Scholar] [CrossRef]
- Piramide, F.; Kowalewski, K.-F.; Cacciamani, G.; Rivero Belenchon, I.; Taratkin, M.; Carbonara, U.; Marchioni, M.; De Groote, R.; Knipper, S.; Pecoraro, A.; et al. Three-dimensional Model-assisted Minimally Invasive Partial Nephrectomy: A Systematic Review with Meta-analysis of Comparative Studies. Eur. Urol. Oncol. 2022, 5, 640–650. [Google Scholar] [CrossRef]
- Mihai, I.; Dura, H.; Teodoru, C.A.; Todor, S.B.; Ichim, C.; Grigore, N.; Mohor, C.I.; Mihetiu, A.; Oprinca, G.; Bacalbasa, N.; et al. Intraoperative Ultrasound: Bridging the Gap between Laparoscopy and Surgical Precision during 3D Laparoscopic Partial Nephrectomies. Diagnostics 2024, 14, 942. [Google Scholar] [CrossRef] [PubMed]
- Grosso, A.A.; Lambertini, L.; Di Maida, F.; Gallo, M.L.; Mari, A.; Minervini, A. Three-dimensional reconstruction and intraoperative ultrasonography: Crucial tools to safely approach highly complex renal masses. Int. Braz. J. Urol. 2022, 48, 966–997. [Google Scholar] [CrossRef]
- Hu, A.; Lv, Z.; Chen, G.; Lin, Y.; Zhu, X.; Li, J.; Yu, X. Comparison of single-port versus multi-port robotic assisted partial nephrectomy: A systematic review and meta-analysis of perioperative and oncological outcomes. J. Robot. Surg. 2024, 18, 321. [Google Scholar] [CrossRef]
- Hinata, N.; Murakami, S.; Nakano, Y.; Hara, I.; Kondo, T.; Hamamoto, S.; Shiroki, R.; Nagayama, J.; Kawakita, M.; Eto, M.; et al. Efficacy of robot-assisted partial nephrectomy compared to conventional laparoscopic partial nephrectomy for completely endophytic renal tumor: A multicenter, prospective study. Int. J. Clin. Oncol. 2024, 29, 1548–1556. [Google Scholar] [CrossRef]
- Gu, L.; Liu, K.; Shen, D.; Li, H.; Gao, Y.; Huang, Q.; Fan, Y.; Ai, Q.; Xie, Y.; Yao, Y.; et al. Comparison of Robot-Assisted and Laparoscopic Partial Nephrectomy for Completely Endophytic Renal Tumors: A High-Volume Center Experience. J. Endourol. 2020, 34, 581–587. [Google Scholar] [CrossRef] [PubMed]
- Bravi, C.A.; Larcher, A.; Capitanio, U.; Mari, A.; Antonelli, A.; Artibani, W.; Barale, M.; Bertini, R.; Bove, P.; Brunocilla, E.; et al. Perioperative Outcomes of Open, Laparoscopic, and Robotic Partial Nephrectomy: A Prospective Multicenter Observational Study (The RECORd 2 Project). Eur. Urol. Focus 2021, 7, 390–396. [Google Scholar] [CrossRef] [PubMed]
- Ficarra, V.; Novara, G.; Secco, S.; Macchi, V.; Porzionato, A.; De Caro, R.; Artibani, W. Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) Classification of Renal Tumours in Patients who are Candidates for Nephron-Sparing Surgery. Eur. Urol. 2009, 56, 786–793. [Google Scholar] [CrossRef]
- Campi, R.; Grosso, A.A.; Lane, B.R.; DE Cobelli, O.; Sanguedolce, F.; Hatzichristodoulou, G.; Antonelli, A.; Noyes, S.; DI Maida, F.; Mari, A.; et al. Impact of Trifecta definition on rates and predictors of “successful” robotic partial nephrectomy for localized renal masses: Results from the Surface-Intermediate-Base Margin Score International Consortium. Minerva Urol. Nephrol. 2022, 74, 186–193. [Google Scholar] [CrossRef]
- Mari, A.; Tellini, R.; Di Maida, F.; Campi, R.; Barzaghi, P.; Tasso, G.; Sforza, S.; Tuccio, A.; Siena, G.; Masieri, L.; et al. Predictors of early postoperative and mid-term functional outcomes in patients treated with Endoscopic Robot-Assisted Simple Enucleation (ERASE): Results from a tertiary referral center. Minerva Urol. Nefrol. 2020, 72, 490–497. [Google Scholar] [CrossRef]
- Carbonara, U.; Simone, G.; Minervini, A.; Sundaram, C.P.; Larcher, A.; Lee, J.; Checcucci, E.; Fiori, C.; Patel, D.; Meagher, M.; et al. Outcomes of robot-assisted partial nephrectomy for completely endophytic renal tumors: A multicenter analysis. Eur. J. Surg. Oncol. J. Eur. Soc. Surg. Oncol. Br. Assoc. Surg. Oncol. 2021, 47, 1179–1186. [Google Scholar] [CrossRef]
- Minervini, A.; Campi, R.; Di Maida, F.; Mari, A.; Montagnani, I.; Tellini, R.; Tuccio, A.; Siena, G.; Vittori, G.; Lapini, A.; et al. Tumor-parenchyma interface and long-term oncologic outcomes after robotic tumor enucleation for sporadic renal cell carcinoma. Urol. Oncol. 2018, 36, e1–e527. [Google Scholar] [CrossRef]
- Bertolo, R.; Campi, R.; Mir, M.C.; Klatte, T.; Kriegmair, M.C.; Salagierski, M.; Ouzaid, I.; Capitanio, U. Systematic Review and Pooled Analysis of the Impact of Renorrhaphy Techniques on Renal Functional Outcome After Partial Nephrectomy. Eur. Urol. Oncol. 2019, 2, 572–575. [Google Scholar] [CrossRef] [PubMed]
- Minoda, R.; Takagi, T.; Yoshida, K.; Kondo, T.; Tanabe, K. Comparison of Surgical Outcomes Between Enucleation and Standard Resection in Robot-Assisted Partial Nephrectomy for Completely Endophytic Renal Tumors Through a 1:1 Propensity Score-Matched Analysis. J. Endourol. 2021, 35, 1779–1784. [Google Scholar] [CrossRef] [PubMed]
- Santok, G.D.; Abdel Raheem, A.; Chang, K.D.; Kim, L.; Lum, T.G.; Alenzi, M.J.; Han, W.K.; Choi, Y.D.; Rha, K.H. Estimated glomerular filtration rate’s time to nadir after robot-assisted partial nephrectomy: Predictors and clinical significance on renal functional recovery. Int. J. Urol. Off. J. Jpn. Urol. Assoc. 2018, 25, 660–667. [Google Scholar] [CrossRef]
- Denic, A.; Lieske, J.C.; Chakkera, H.A.; Poggio, E.D.; Alexander, M.P.; Singh, P.; Kremers, W.K.; Lerman, L.O.; Rule, A.D. The Substantial Loss of Nephrons in Healthy Human Kidneys with Aging. J. Am. Soc. Nephrol. 2017, 28, 313–320. [Google Scholar] [CrossRef]
- Capitanio, U.; Larcher, A.; Terrone, C.; Antonelli, A.; Volpe, A.; Fiori, C.; Furlan, M.; Deho, F.; Minervini, A.; Serni, S.; et al. End-Stage Renal Disease After Renal Surgery in Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and Individual Disorders at Baseline. Eur. Urol. 2016, 70, 558–561. [Google Scholar] [CrossRef] [PubMed]
- Rosiello, G.; Larcher, A.; Fallara, G.; Cignoli, D.; Re, C.; Martini, A.; Tian, Z.; Karakiewicz, P.I.; Mottrie, A.; Boarin, M.; et al. A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy-A large, retrospective, single-center study. Urol. Oncol. 2023, 41, e17–e149. [Google Scholar] [CrossRef]
- Huang, W.C.; Levey, A.S.; Serio, A.M.; Snyder, M.; Vickers, A.J.; Raj, G.V.; Scardino, P.T.; Russo, P. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: A retrospective cohort study. Lancet. Oncol. 2006, 7, 735–740. [Google Scholar] [CrossRef]
- Schiavina, R.; Mari, A.; Bianchi, L.; Amparore, D.; Antonelli, A.; Artibani, W.; Brunocilla, E.; Capitanio, U.; Fiori, C.; Di Maida, F.; et al. Predicting positive surgical margins in partial nephrectomy: A prospective multicentre observational study (the RECORd 2 project). Eur. J. Surg. Oncol. 2020, 46, 1353–1359. [Google Scholar] [CrossRef]
- Tellini, R.; Antonelli, A.; Tardanico, R.; Fisogni, S.; Veccia, A.; Furlan, M.C.; Carobbio, F.; Cozzoli, A.; Zanotelli, T.; Simeone, C. Positive Surgical Margins Predict Progression-free Survival After Nephron-sparing Surgery for Renal Cell Carcinoma: Results from a Single Center Cohort of 459 Cases with a Minimum Follow-up of 5 Years. Clin. Genitourin. Cancer 2019, 17, e26–e31. [Google Scholar] [CrossRef]
- Pandolfo, S.D.; Cerrato, C.; Wu, Z.; Franco, A.; Del Giudice, F.; Sciarra, A.; Verze, P.; Lucarelli, G.; Imbimbo, C.; Perdonà, S.; et al. A systematic review of robot-assisted partial nephrectomy outcomes for advanced indications: Large tumors (cT2-T3), solitary kidney, completely endophytic, hilar, recurrent, and multiple renal tumors. Asian J. Urol. 2023, 10, 390–406. [Google Scholar] [CrossRef] [PubMed]
Preoperative Features | Total (n = 211) | Open (n = 94) | Laparoscopic (n = 52) | Robotic (n = 65) | p Value | |
---|---|---|---|---|---|---|
Age (years), median IQR | 63.6 (52.9−70.9) | 66 (54.8−72.6) | 61.7 (49.5−67.4) | 60.1 (51.6−68.9) | 0.04 | |
Gender, n% |
| 143 (67.8) | 60 (63.8) | 40 (76.9) | 43 (66.2) | 0.26 |
| 68 (32.2) | 34 (36.2) | 12 (23.1) | 22 (33.8) | ||
BMI (kg/m2), median IQR | 25.8 (23.7−28.7) | 25.5 (23.5−28.4) | 26.1 (24.0−28.2) | 26.1 (23.9−28.9) | 0.87 | |
ECOG Score | median IQR | 0 (0−0) | 0 (0−1) | 0 (0−0) | 0 (0−1) | 0.16 |
| 49 (23.2) | 17 (18.1) | 12 (23.1) | 20 (30.7) | 0.19 | |
ASA Score | median IQR | 2 (2−3) | 2 (2−3) | 2 (2−3) | 2 (2−2) | 0.01 |
| 53 (25.1) | 27 (28.7) | 15 (28.8) | 11 (16.9) | 0.41 | |
CCI PS score, median IQR | 0 (0−0) | 0 (0−2) | 0 (0−1) | 0 (0−2) | 0.52 | |
AA-CCI PS score, median IQR | 4 (2−5) | 3 (2−4) | 3 (2−4) | 0.05 | ||
Surgical indication, n % |
| 187 (88.9) | 83 (88.3) | 47 (90.4) | 57 (87.7) | 0.89 |
| 19 (9.0) | 7 (7.4) | 4 (7.7) | 8 (12.3) | ||
| 5 (2.4) | 4 (4.3) | 1 (1.9) | 0 (0.0) | ||
Tumor side, n. % |
| 122 (57.8) | 57 (60.6) | 28 (53.8) | 37 (56.9) | 0.74 |
| 86 (40.8) | 35 (37.2) | 23 (44.2) | 28 (43.1) | ||
| 3 (1.4) | 2 (2.1) | 1 (1.9) | 0 (0.0) | ||
Clinical T, n. % |
| 178 (84.4) | 81(86.2) | 43 (82.7) | 54 (83.1) | 0.82 |
| 29 (13.7) | 11 (11.7) | 8 (15.4) | 10 (15.4) | ||
| 1 (0.5) | 1 (1.1) | 0 (0.0) | 0 (0.0) | ||
| 3 (1.4) | 1 (1.1) | 1 (1.9) | 1 (1.5) | ||
Multiple ipsilateral lesion, n. % | 10 (4.7) | 6 (6.4) | 1 (1.9) | 3 (4.6) | 0.48 | |
Renal margin, n. % |
| 100 (47.4) | 43 (45.7) | 27 (51.9) | 30 (46.2) | 0.75 |
| 111 (52.6) | 51 (54.3) | 25 (48.1) | 35 (53.8) | ||
Renal face, n. % |
| 115 (54.5) | 54 (57.4) | 26 (50.0) | 35 (53.8) | 0.68 |
| 96 (45.5) | 40 (42.6) | 26 (50.0) | 30 (46.2) | ||
Tumor location relative to the polar line (PL), n % |
| 63 (29.9) | 20 (21.3) | 20 (38.5) | 23 (35.4) | 0.35 |
| 83 (39.3) | 45 (47.9) | 16 (30.8) | 22 (33.8) | ||
| 65 (30.8) | 29 (30.9) | 16 (30.8) | 20 (30.8) | ||
PADUA score, median IQR | 10 (9−11) | 10 (9−11) | 9 (9−11) | 10 (9−11) | 0.24 | |
PADUA risk classes, n % |
| 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0.21 |
| 85 (40.3) | 33 (35.1) | 26 (50.0) | 26 (40.0) | ||
| 126 (59.7) | 61 (64.9) | 26 (50.0) | 39 (60.0) | ||
RENAL score, median IQR | 9 (8−10) | 9 (8−10) | 8 (7−9) | 8 (7−10) | 0.10 | |
Preoperative biopsy, n % | 7 (3.3) | 3 (3.2) | 1 (1.9) | 3 (4.6) | 0.72 | |
Baseline hemoglobin (mg/dL), median (IQR) | 14.3 (13.4−15.1) | 14.3 (13.3−15.1) | 14.5 (13.4−15.1) | 14.3 (13.4−15.3) | 0.74 | |
Baseline creatinine (mg/dL), median (IQR) | 0.9 (0.8−1.1) | 0.9 (0.7−1.0) | 0.95 (0.8−1.1) | 0.9 (0.8−1.1) | 0.06 | |
Baseline eGFR (mL/min), median IQR | 85.1 (71.9−100.7) | 88.2 (74.2−103.4) | 84.5 (69.6−101.1) | 82.4 (72.4−95.8) | 0.45 |
Surgical Features | Open (n = 94) | Laparoscopic (n = 52) | Robotic (n = 65) | p Value | |
---|---|---|---|---|---|
Approach, n. % | Transperitoneal | 12 (12.8) | 36 (69.2) | 52 (80.0) | 0.001 |
Retroperitoneal | 82 (87.2) | 16 (30.8) | 13 (20.0) | ||
Type of resection, n. % | Pure Enucleation | 13 (13.8) | 7 (13.5) | 26 (40.0) | 0.001 |
Standard PN | 81 (86.2) | 45 (86.5) | 39 (60.0) | ||
Hilar clamping, n. % | Performed | 57 (60.6) | 29 (55.8) | 45 (69.2) | 0.31 |
Not performed | 37 (39.4) | 23 (44.2) | 20 (30.8) | ||
Warm ischemia time (min), median IQR | 17 (13−23) | 15 (12.5−22.5) | 18 (13−24) | 0.74 | |
Volume center (number of PN/year in each center), median IQR | 62 (37−75) | 49.5 (32−79) | 71 (43.5−118) | 0.04 | |
Patients treated in centers performing > 30 PN/year, n. % | 75 (79.8) | 42 (80.8) | 50 (76.9) | 0.86 | |
Patients treated in centers performing > 50 PN/year, n. % | 59 (62.8) | 32 (61.5) | 51 (78.5) | 0.07 | |
EBL (cc), median IQR | 185 (87.5−362.5) | 175 (57−475) | 100 (60−200) | 0.04 | |
Operative time (minutes), median IQR | 140 (110−170) | 160 (132−215) | 126 (90−175) | 0.01 | |
Hemostatic agents, n. % | 27 (28.7) | 4 (7.7) | 16 (24.6) | 0.01 | |
Renorrhaphy, n. % | 90 (95.7) | 50 (96.2) | 55 (84.6) | 0.02 | |
Intraoperative surgical complications, n. % | 3 (3.2) | 3 (5.8) | 2 (3.1) | 0.69 | |
Conversion rate, n. % | 0 (0.0) | 1 (1.9) | 0 (0.0) | 0.22 | |
Postoperative surgical complications, n. (%) | 15 (16.0) | 4 (7.7) | 5 (7.7) | 0.06 | |
| 2 (2.1) | 1 (1.9) | 1 (1.5) | 0.54 | |
Medical complications, n. (%) | 4 (4.2) | 2 (3.8) | 2 (3.1) | 0.36 | |
Time do drainage removal (days), median (IQR) | 4 (3−5) | 3 (2−4) | 3 (2−4) | 0.04 | |
Length of stay (days), median (IQR) | 5 (5−6) | 3 (3−4) | 3 (3−4) | 0.01 | |
Trifecta rate, n. % | 38 (40.2) | 33 (63.5) | 42 (64.6) | 0.03 |
Pathological Features | Open (n = 94) | Laparoscopic (n = 52) | Robotic (n = 65) | p Value | |
---|---|---|---|---|---|
Pathological diameter, median (IQR) | 3 (2−4) | 3 (2−4) | 3 (2−3) | 0.39 | |
Tumor histotype, n. % | • Clear cell RCC | 63 (67.0) | 28 (53.8) | 43 (66.2) | 0.95 |
• Papillary RCC | 7 (7.4) | 7 (13.5) | 8 (12.3) | ||
• Chromophobe RCC | 4 (4.3) | 8 (15.4) | 3 (4.6) | ||
• Oncocytoma | 13 (13.8) | 4 (7.7) | 10 (15.4) | ||
• Angiomiolypoma | 2 (2.1) | 1 (1.9) | 0 (0.0) | ||
• Other | 5 (5.3) | 4 (7.7) | 1 (1.5) | ||
Fuhrman grade, n. % | • Grade 1 | 6 (6.4) | 3 (5.8) | 4 (6.2) | 0.96 |
• Grade 2 | 47 (50.0) | 26 (50.0) | 35 (53.8) | ||
• Grade 3 | 17 (18.1) | 9 (17.3) | 13 (20.0) | ||
• Grade 4 | 1 (1.1) | 1 (1.9) | 0 (0.0) | ||
• Absent/not applicable | 23 (24.5) | 13 (25.0) | 13 (20.0) | ||
pT stage, n. % | • pT1a | 62 (66.0) | 33 (63.5) | 42 (64.6) | 0.62 |
• pT1b | 17 (18.1) | 8 (15.4) | 10 (15.4) | ||
• pT3a | 1 (1.1) | 5 (9.6) | 3 (4.6) | ||
• Absent/not applicable | 14 (14.9) | 6 (11.5) | 10 (15.4) | ||
Positive surgical margins, n. % | 7 (7.4) | 6 (11.5) | 5 (7.8) | 0.62 | |
Urinary calyceal system invasion, n. % | 0 (0.0) | 2 (3.8) | 3 (4.6) | 0.12 | |
Lymphovascular invasion, n. % | 4 (4.3) | 4 (7.7) | 1 (1.5) | 0.26 | |
Tumor necrosis, n. % | 10 (10.6) | 9 (17.3) | 6 (9.2) | 0.36 |
Functional Outcomes | Open (n = 94) | Laparoscopic (n = 52) | Robotic (n = 65) | p Value |
---|---|---|---|---|
eGFR at 1 month follow up, median (IQR) | 66.8 (54.6−83.2) | 71.1 (57.9−87.5) | 75.1 (58.4−89.7) | 0.04 |
Preop—1 month follow up Δ eGFR, (%) (IQR) | 24.3 (9.4−32.2) | 15.9 (7.4−22.3) | 8.9 (2.3−14.2) | 0.01 |
>25% RF loss at 1 month follow up, n (%) | 40 (42.6) | 17 (32.7) | 10 (15.4) | 0.01 |
eGFR at 12 months follow up, median (IQR) | 73.2 (60.5−88.3) | 75.3 (60.4−91.4) | 76.2 (62.6−90.4) | 0.28 |
Preop—12 months follow up Δ eGFR, (%) (IQR) | 17 (5.4−29.8) | 10.9 (3.9−17.4) | 7.5 (2.4−15.6) | 0.03 |
>25% RF loss at 12 months follow up, n (%) | 24 (25.5) | 12 (23.1) | 8 (12.3) | 0.01 |
eGFR at 24 months follow up, median (IQR) | 76.6 (64.4−95.3) | 79.4 (65.6−97.3) | 78.7 (69.3−98.5) | 0.42 |
RF Loss > 25% at 1 Month Follow Up | Trifecta Failure | ||||||
---|---|---|---|---|---|---|---|
Covariates | OR | 95%CI | p value | OR | 95%CI | p value | |
Age at surgery | 1.05 | 1.01−1.11 | 0.04 | 1.05 | 1.01−1.11 | 0.04 | |
Gender | Male | 0.78 | 0.35−1.74 | 0.54 | 0.89 | 0.41−1.95 | 0.79 |
Female (ref) | - | - | - | - | - | - | |
Charlson comorbidity index | 0.99 | 0.74−1.33 | 0.97 | 1.02 | 0.69−1.21 | 0.54 | |
Preoperative eGFR | 1.03 | 1.01−1.06 | 0.01 | 1.01 | 0.99−1.04 | 0.21 | |
PADUA score | 1.18 | 0.86−1.62 | 0.31 | 1.16 | 0.86−1.56 | 0.33 | |
WIT | 1.02 | 0.96−1.06 | 0.63 | 1.01 | 0.96−1.06 | 0.67 | |
Surgical approach | Open | 1.76 | 1.12−4.38 | 0.02 | 2.42 | 1.02−5.76 | 0.04 |
Laparoscopic | 1.12 | 0.33−2.86 | 0.23 | 1.87 | 0.69−5.05 | 0.22 | |
Robotic (ref) | - | - | - | - | - | - |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Di Maida, F.; Mari, A.; Amparore, D.; Antonelli, A.; Schiavina, R.; Bertolo, R.G.; Veccia, A.; Brunocilla, E.; Campi, R.; Da Pozzo, L.; et al. Perioperative and Mid-Term Oncological and Functional Outcomes After Partial Nephrectomy for Entirely Endophytic Renal Tumors: A Prospective Multicenter Observational Study (The RECORD2 Project). Cancers 2025, 17, 1236. https://doi.org/10.3390/cancers17071236
Di Maida F, Mari A, Amparore D, Antonelli A, Schiavina R, Bertolo RG, Veccia A, Brunocilla E, Campi R, Da Pozzo L, et al. Perioperative and Mid-Term Oncological and Functional Outcomes After Partial Nephrectomy for Entirely Endophytic Renal Tumors: A Prospective Multicenter Observational Study (The RECORD2 Project). Cancers. 2025; 17(7):1236. https://doi.org/10.3390/cancers17071236
Chicago/Turabian StyleDi Maida, Fabrizio, Andrea Mari, Daniele Amparore, Alessandro Antonelli, Riccardo Schiavina, Riccardo Giuseppe Bertolo, Alessandro Veccia, Eugenio Brunocilla, Riccardo Campi, Luigi Da Pozzo, and et al. 2025. "Perioperative and Mid-Term Oncological and Functional Outcomes After Partial Nephrectomy for Entirely Endophytic Renal Tumors: A Prospective Multicenter Observational Study (The RECORD2 Project)" Cancers 17, no. 7: 1236. https://doi.org/10.3390/cancers17071236
APA StyleDi Maida, F., Mari, A., Amparore, D., Antonelli, A., Schiavina, R., Bertolo, R. G., Veccia, A., Brunocilla, E., Campi, R., Da Pozzo, L., Fiori, C., Gontero, P., Grosso, A. A., Lambertini, L., Longo, N., Imbimbo, C., Briganti, A., Montorsi, F., Porpiglia, F., ... Minervini, A. (2025). Perioperative and Mid-Term Oncological and Functional Outcomes After Partial Nephrectomy for Entirely Endophytic Renal Tumors: A Prospective Multicenter Observational Study (The RECORD2 Project). Cancers, 17(7), 1236. https://doi.org/10.3390/cancers17071236